Osimertinib / Osimertinib Drug Encyclopedia

Osimertinib/Osimertinib (Osimertinib), also known as mesylateOsimertinib/Osimertinibtablet is an oral targeted therapy drug, mainly used to treat advanced non-small cell lung cancer (NSCLC) with positive EGFR gene mutations. EGFR (Epidermal Growth Factor Receptor) is a receptor tyrosine kinase located on the cell membrane, involved in regulating key physiological processes such as cell growth, proliferation and survival. In some NSCLC patients, there are EGFR gene mutations, which lead to abnormal proliferation of tumor cells. Osimertinib/Osimertinib is the treatment drug for this specific patient group.

Osimertinib/The mechanism of action of Osimertinib mainly includes the following aspects:

1.EGFRtyrosine kinase inhibition:Osimertinib/Osimertinib is a highly selective EGFRtyrosine kinase inhibitor. It interacts with the ATP binding site of EGFR, inhibits the activity of EGFR, blocks the conduction of the EGFR signaling pathway, thereby inhibiting the growth and spread of tumor cells.

2.Targeting specificEGFRmutations:Osimertinib/Osimertinib is particularly suitable for treatmentEGFRgene mutation-positiveNSCLC patients, such as Del19, L858R, etc. It can target these specific EGFRThe mutation exerts its inhibitory effect and reduces the activity of tumor cells, thereby prolonging the patient's disease progression-free time and survival.

3.Overcoming drug resistance: For patients who have previously been treated with other EGFR inhibitors and developed drug resistance, Osimertinib/Osimertinib has shown good resistance treatment effects. It can target the drug resistance caused by the EGFR T790M mutation and restore sensitivity to EGFR inhibitors, thereby continuing to inhibit tumor growth.

4.Good therapeutic effect on brain metastases:Osimertinib/Osimertinib has good intracerebral permeability and can effectively inhibit the growth and spread of brain metastases, providing an effective brain metastasis treatment option for patients with advanced NSCLC.

In general, Osimertinib/Osimertinib is a targeted therapy for EGFRgene mutation-positive advanced NSCLC. It provides patients with effective treatment options and improves their survival rate and quality of life by inhibiting the EGFR signaling pathway, targeting specific EGFR mutations, overcoming drug resistance, and achieving good therapeutic effects on brain metastases.